StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
NASDAQ GLMD opened at $0.39 on Wednesday. Galmed Pharmaceuticals has a one year low of $0.26 and a one year high of $7.80. The company’s 50 day moving average price is $0.36 and its 200 day moving average price is $0.38. The firm has a market capitalization of $1.98 million, a price-to-earnings ratio of -0.12 and a beta of 0.87.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) EPS for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- Using the MarketBeat Stock Split Calculator
- MarketBeat Week in Review – 4/22 – 4/26
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Stocks Leading the U.S. Agriculture Comeback
- The Most Important Warren Buffett Stock for Investors: His Own
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
